Linolenic Acid.

Both fatty acids are handled by the same delta-6 desaturase, and the far larger dietary load of linoleic acid crowds out alpha-linolenic conversion. Lowering omega-6 raises the share of alpha-linolenic acid that moves onward.

Alpha-linolenic acid is desaturated and elongated to EPA, but the conversion in adults is a small percentage of intake. Supplying EPA directly bypasses the bottleneck rather than adding to it.

The route from alpha-linolenic acid to DHA passes through EPA and a peroxisomal step, and the yield is lower still than for EPA. Plant omega-3 and preformed DHA are complementary rather than interchangeable.

Flaxseed oil is roughly half alpha-linolenic acid, so listing both delivers the same fatty acid twice. Total omega-3 should be read across the two lines.

Alpha-linolenic acid oxidises readily because of its three double bonds, and alpha-tocopherol interrupts the resulting lipid radical chain. Oils high in it are routinely stabilised with tocopherols for this reason.

Desaturase enzymes that act on alpha-linolenic acid work less well when zinc status is low. Adequate zinc keeps the already-limited conversion to longer chain omega-3 from falling further.

Pyridoxine is one of the cofactors associated with normal desaturase and elongase function in fatty acid chains. Marginal B6 status is one reason conversion rates vary between people.

Alpha-linolenic acid carries three double bonds, which makes it one of the more oxidation-prone fatty acids in a formula. Vitamin E intercepts the peroxyl radicals that propagate that chain, and ascorbate reduces the tocopheryl radical back to tocopherol so the same molecule can act again. Vitamin C therefore supports the antioxidant system that keeps polyunsaturated oils intact rather than acting on the fatty acid itself.

Glutathione peroxidases are selenoenzymes, and one of them reduces lipid hydroperoxides formed in membrane phospholipids. Diets rich in polyunsaturated fatty acids place more demand on that reduction step. Selenium status is what allows the enzyme to be built, so it sits upstream of how well incorporated ALA is handled once it is in a membrane.

ALA arrives as a triglyceride and cannot be absorbed until it is emulsified and packaged into mixed micelles. Bile salts provide that emulsification at the intestinal brush border. Where bile output is low, fat-soluble material including ALA-rich oils is absorbed less completely, which is why bile components appear alongside oils in formulation.

Pancreatic lipase hydrolyses dietary triglycerides at the sn-1 and sn-3 positions, releasing free fatty acids and a 2-monoacylglycerol. That hydrolysis is the step that liberates ALA from the seed-oil triglyceride. Supplemental lipase is used in formulation on that established digestive step, not on any separate action of the fatty acid.

Vitamin D3 is fat-soluble and its uptake depends on dietary lipid being present to form micelles. An ALA-rich oil supplies that lipid vehicle. The pairing is about the vehicle, and it says nothing about either nutrient changing the other's function once absorbed.

Menaquinone-7 is highly lipophilic and is routinely suspended in an oil for delivery. Flaxseed and other ALA-rich oils serve that role. The relationship is a delivery one, and the fatty acid contributes no vitamin K activity of its own.

Carotenoid absorption rises with co-ingested fat because carotenoids need micellar incorporation to cross the enterocyte. An ALA-rich oil taken in the same meal supplies that fat. Note this is a general lipid effect rather than anything specific to the n-3 double bonds.

Beta-carotene shares the same micelle-dependent absorption route as other carotenoids and is taken up more completely when fat is present. ALA-rich oils are one such fat source. At high carotenoid loads the carotenoids compete with each other, so the benefit is to absorption of the mixture, not to any single one.

Astaxanthin is a lipid-phase antioxidant that sits within membranes and oil droplets, exactly where polyunsaturated fatty acids are vulnerable to peroxyl radical attack. Formulators pair carotenoid antioxidants with n-3 oils on that chemistry. Human data on the combination changing a clinical outcome is not what grounds this row.

Rosemary extract standardised to carnosic acid and carnosol is a widely used oil-phase antioxidant in polyunsaturated oils. It slows the formation of primary and secondary oxidation products during storage. The role is protecting the oil in the bottle, which is a stability property and not a physiological effect in the person taking it.

Lecithin is an amphiphilic phospholipid mixture that disperses oils into stable emulsions. ALA-rich oils are emulsified with it for beverages, powders and soft-gel fills. Emulsification also creates a finer droplet size at the point of digestion, which is the practical reason it is chosen.

Free ferrous iron catalyses the decomposition of lipid hydroperoxides into radicals, which propagates peroxidation in polyunsaturated oils. Co-formulating an unchelated iron salt directly with an ALA-rich oil is therefore a stability problem rather than a synergy. Chelated iron forms and physical separation are the standard responses in manufacturing.

Copper ions, like iron, catalyse lipid peroxidation of polyunsaturated fatty acids in vitro. The relevance is greatest in the product itself, where trace metal contamination shortens oxidative shelf life. This is a formulation caution, not a statement about copper intake in the diet.

Medium-chain triglycerides are absorbed largely as free fatty acids into the portal circulation without needing chylomicron packaging, while ALA takes the lymphatic chylomicron route. The two therefore do not compete for the same carrier capacity. MCT is often used as a carrier oil where a low-viscosity, oxidation-stable base is wanted.

Dihydrolipoic acid can reduce oxidised forms of other antioxidants including tocopheryl and ascorbyl radicals in laboratory systems. That places it in the same recycling network that protects polyunsaturated fatty acids from peroxidation. The evidence here is mechanistic chemistry rather than a human combination trial.

Reduced coenzyme Q10 acts as a lipid-phase antioxidant within membranes and can regenerate alpha-tocopherol from its radical form. Membranes enriched in ALA and its elongation products are the compartment where that matters. It is also commonly delivered in the same oil base, which is a separate practical reason the two appear together.

Catechins slow oxidation of polyunsaturated oils in laboratory model systems. That work is done in the oil phase and in emulsions, not in people. It supports EGCG as an oil-stability agent and nothing more than that here.